Objective-Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals on interaction with its 2 ligands, PD-L1 and PD-L2. We studied the contribution of the PD-1 pathway to regulation of T cells that promote atherosclerotic lesion formation and inflammation.
C D4 ϩ Th1 cells contribute significantly to the progression of atherosclerosis. 1 Previous work from our laboratory has demonstrated the importance of the B7/CD28 costimulatory pathway in the priming of proatherogenic Th1 responses. 2 Negative regulatory ("coinhibitory") members of the B7/CD28 family are also important modulators of T-cell responses in a variety of disease conditions. The programmed cell death-1 (PD-1) receptor binds programmed death-ligand 1 (PD-L1) and PD-L2 (also known as B7-H1 and B7-DC, respectively). 3 PD-1 is inducibly expressed on T cells, B cells, macrophages, and some types of dendritic cells. PD-L1 is expressed on both hematopoietic and nonhematopoietic cells types. In contrast, PD-L2 expression is restricted mainly to dendritic cells and macrophages. 4 PD-1 and PD-L1 interactions have been implicated in controlling immune tolerance, autoimmunity, and immune responses to viral infections and tumors. [5] [6] [7] [8] Persistent antigenic stimulation in the setting of chronic viral infection leads to sustained upregulation of PD-1 expression on viral-specific CD8 ϩ cytotoxic T lymphocytes (CTL) and contributes to T-cell exhaustion; therefore, antibody-mediated blockade of PD-1 or PD-L1 is being studied as a new therapeutic approach for chronic viral infections and cancer. 5, 9, 10 We have shown that PD-L1 is expressed on both dendritic cells and macrophages in aortic lesions in hypercholesterolemic low-density lipoprotein receptor knockout (Ldlr Ϫ/Ϫ ) mice, and hypercholesterolemic Ldlr Ϫ/Ϫ mice that lack PD-L1 and PD-L2 develop significantly increased atherosclerosis with more lesional T cells compared with Ldlr Ϫ/Ϫ controls. 11 However, the role of PD-1 in regulating proatherogenic T-cell responses has not been directly examined. PD-1 is known to inhibit T-cell activation by binding to B7-1, as well as to PD-L1 and PD-L2, 12 and it is possible that other receptors for PD-L1 exist. 13 Because PD-1, and not PD-L1 or PD-L2, is the target of new therapies being developed for cancer and chronic viral infections, it is important to know whether PD-1 is required to regulate proatherogenic T-cell responses in the arterial wall. Here we describe in vivo studies that directly address this question.
Animal Studies
Pd1 Ϫ/Ϫ mice on a C57BL/6 background, derived by targeted mutation in C57BL/6 ES cells, which results in deletion of the IgV domain as described, 14 were crossbred with the Ldlr Ϫ/Ϫ mice on a C57BL/6 background (Jackson Laboratory) to establish Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ double-knockout mice. Pd-l1/2 Ϫ/Ϫ mice, derived as described 15 or C57BL/6 mice (Jackson laboratories) were used as bone marrow donors to produce Pd-l1/2 Ϫ/Ϫ 3Ldlr Ϫ/Ϫ or Pd-l1/2 ϩ/ϩ 3Ldlr Ϫ/Ϫ radiation chimeras, as described. 16 Some Ldlr Ϫ/Ϫ mice were injected intraperitoneally with anti-mouse PD-1 antibody (29F.1A12.D5, prepared in-house) or rat IgG2a (Bio X Cell, catalog no. BE0089), 200 g/mouse, twice a week for 3 weeks. Pd1 Ϫ/Ϫ OT-1 transgenic mice were generated by backcrossing Pd1 Ϫ/Ϫ mice with OT-1 T-cell receptor (TCR) transgenic mice. 17 All the mice were given water ad libitum and were maintained on a 12/12-hour light/dark cycle under pathogen-free conditions in the Harvard new research building animal facility according to institutional and National Institutes of Health guidelines.
Serum Lipid Analysis
Mice lipid profiles were measured on the c501 module of the Cobas 6000 analyzer (Roche Diagnostics, Indianapolis, IN) using the assays developed for human use.
Multiplexed Cytokine Assays
Sera and culture supernatants were analyzed for cytokine concentrations using Luminex bead-based multiplex assays.
Atherosclerotic Lesion Assessment
Atherosclerotic lesions were analyzed in the aortic root, aortic arch, and descending aorta as previously described. 11, 16 
Immunohistochemistry and Double Immunofluorescence Staining of Aortic Lesions
Frozen aortic root sections were stained with antibodies specific for CD4, CD8, F4/80 for macrophages, and smooth muscle cell-␣ actin (SMC-␣ actin) for SMC, as described. 11, 16 Double immunofluorescence staining for CD3 and CD4 or CD8 was performed in the aortic sinus sections, as well as for SMC (SMC-␣ actin, fluorescein isothiocyanate, Sigma-Aldrich) and annexin V (Alexa Fluor 568, Invitrogen). Nuclei were stained with 4Ј,6-diamidino-2-phenylindole (DAPI).
Cell Immunostaining and Flow Cytometry
Splenocytes, iliac node lymphocytes, and aortic digests were stained for CD3, CD4, CD8, CD62L, CD25, CD44, and PD-1. Aortas from the ascending aorta to iliac bifurcation were cleaned of periadventitial connective tissue and subjected to enzymatic digestion, as described. 18 
CTL Killing Assay
Mouse aortic SMC and mouse heart endothelial cells (EC) were prepared as previously described 19, 20 and cocultured with mouse Pd1 Ϫ/Ϫ OT-1 or Pd1 ϩ/ϩ CD8 ϩ OT-1 CTL plus SIINFKL peptide antigen for 2 hours. Apoptotic cells were then quantified by annexin V/7-aminoactinomycin D (7-AAD) staining and flow cytometry.
CD4 ؉ and CD8 ؉ T-Cell Purifications and Quantitative Reverse Transcription-Polymerase Chain Reaction Analyses
Splenic CD4 ϩ or CD8 ϩ T cells were purified by immunomagnetic beads, and RNA was isolated, reverse transcribed, and subjected to quantitative reverse transcription-polymerase chain reaction analyses for the genes listed in Supplemental Table IV .
In Vitro Cell Proliferation Assay
CD4 ϩ and CD8 ϩ T cells were purified from spleen and lymph node of mice and stimulated with ␣CD3 or oxidized low-density lipopro-tein (oxLDL) in vitro, and proliferation was measured by 3 Hthymidine incorporation.
Statistics
All statistical analyses were performed using Prism software. Differences between 2 groups of mice were analyzed by Student t test and expressed as meanϮSEM or by the Mann-Whitney test (for nonparametric data). For experiments with 3 or more groups, ANOVA with the Tukey multiple comparison post test was used. A value of PϽ0.05 was considered significant.
Results

Atherosclerotic Lesion Development and Phenotype in Pd1 ؊/؊ Ldlr ؊/؊ Mice
We generated Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice by crossbreeding the relevant parent strains, and we compared lesion development in Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice fed a cholesterol diet for 5 and 10 weeks. 2, 11 Serum lipids did not differ significantly between the 2 groups of mice after either 5 or 10 weeks of this diet ( Supplemental Table I ). At 5 weeks, lesion size was similar in both groups (Figure 1a and 1c ), but the lesions of the PD-1-deficient mice had markedly more inflammatory cells, including CD4 ϩ and CD8 ϩ T cells and macrophages (Figure 2a and 2b). After 10 weeks of the diet, the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice had increased lesion size compared with Ldlr Ϫ/Ϫ controls (Figure 1a and 1c). The percentage of the total cross-sectional vessel wall area occupied by lesion was increased, and there was an outward remodeling, resulting in an increase in total aortic root cross sectional area in Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ controls ( Figure  1a ). Additionally, en face lesional analysis of the entire aorta distal to the aortic root revealed more lesions in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice than in the Ldlr Ϫ/Ϫ controls (Figure 1b and 1d ). Immunohistochemical staining revealed more abundant CD4 ϩ and CD8 ϩ T cells and macrophages in the lesions of Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ mice (Figure 2a and 2b). SMC content was similar in the lesions of both groups of mice (Figure 2a and 2b, bottom panels). All these data indicate that PD-1 acts to limit proatherogenic immune responses.
Effects of PD-1 Deficiency on Lesional Cell Death and CTL Cytotoxicity
The increased number of CD8 ϩ T cells in lesions of Pd1 Ϫ/Ϫ mice and the lack of increased SMC content despite an overall increase in lesion size suggested that PD-1 deficiency may cause more CD8ϩ CTL cytotoxicity and SMC death in the lesions. We therefore performed double immunofluorescence staining of aortic sinus of the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice for annexin V (to detect apoptotic cells) and SMC-␣ actin (to detect SMC). We found more apoptotic cells, including SMC and non-SMC ( Figure 3a and 3b ), in the lesions of PD-1-deficient mice after 10 weeks of diet, compared with the lesions from control mice. We did not detect any annexin V-positive lesional SMC at 5 weeks of diet (data not shown). We also performed an in vitro CTL killing assay by coculturing mouse aortic SMC or heart EC with Pd1 Ϫ/Ϫ or control CD8 ϩ CTL from OT-1 TCR transgenic mice. Fluorescence-activated cell sorting (FACS) analyses of annexin V/7-AAD-stained cells demonstrated that effector Pd1 Ϫ/Ϫ OT-1 cells kill more SMC or ECs compared with Pd1 ϩ/ϩ OT-1 ( Figure 3c ).
Effects of PD-1 Deficiency on T-Cell Gene Expression and Immune Responses in Ldlr ؊/؊ Mice
To determine why CD4 ϩ and CD8 ϩ T-cell infiltration was greater in the lesions of hypercholesterolemic Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice, we analyzed expression of selected genes by quantitative reverse transcription-polymerase chain reaction of RNA from purified splenic CD4 ϩ and CD8 ϩ T cells, taken after 10 weeks of cholesterol diet. The results demonstrated that both PD-1-deficient CD4 ϩ and CD8 ϩ T cells expressed higher levels of proinflammatory cytokine genes Ifng and Tnf, as well as increased levels of chemokine receptor genes Ccr5, Ccr6, and Cxcr3, compared with T cells from Ldlr Ϫ/Ϫ mice (Figure 4a and 4b). These data suggested that PD-1-deficient T cells may be more competent at migrating to inflammatory sites compared with wild-type T cells and that they produce more inflammatory cytokines.
To evaluate the changes in T-cell activation in the absence of PD-1 in the context of atherosclerosis, we examined iliac lymph nodes and spleens from hypercholesterolemic Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice. After 5 weeks of diet, there was no difference in the number of iliac lymph node cells between these 2 groups (Supplemental Figure Ia) . However, FACS analyses showed that there were more total CD4 ϩ T cells and a higher fraction of activated CD4 ϩ and CD8 ϩ T cells (CD25 ϩ ) compared with T cells from control mice. (Supplemental Figure Ib to Ie), although the number of splenic CD4 ϩ and CD8 ϩ T cells and the fraction of activated T cells in the spleens were similar between these 2 groups after 5 or 10 weeks of diet (data not shown). Therefore, we asked whether the iliac lymphocyte response to TCR stimulation might be different when PD-1 signaling is absent in the hypercholesterolemic Ldlr Ϫ/Ϫ mice. Polyclonal stimulation of the splenic CD4 ϩ or CD8 ϩ T cells by ␣CD3 resulted in higher levels of interferon-␥ (IFN-␥) production by CD8 ϩ T cells ( Figure 4c ) but not CD4 ϩ T cells (data not shown). Neither splenic CD8 ϩ nor CD4 ϩ T cells responded to the putative athero-antigen oxLDL in vitro (data not shown). When exposed to ␣CD3 (a T cell-specific stimulus) or oxLDL (which could activate antigen-specific T cells and macrophages), the iliac lymph node cells from Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice proliferated more than those from control Ldlr Ϫ/Ϫ mice (Figure 4d and 4e), and they secreted more tumor necrosis factor-␣ (TNF-␣) ( Figure 4f ). It is possible that some of the TNF-␣ that we measured in response to anti-CD3 was produced by macrophages secondarily activated by T-cell IFN-␥. Furthermore, there was a significantly increased level of serum TNF-␣ in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice after 10 weeks of cholesterol diet compared with Ldlr Ϫ/Ϫ mice (Figure 4g ).
Effects of PD-1 Blocking Antibody Administration on Atherosclerotic Lesions in Ldlr ؊/؊ Mice
We next evaluated the impact of an anti-PD-1 blocking antibody on atherosclerosis. Six-week-old Ldlr Ϫ/Ϫ mice were fed a cholesterol diet for 5 weeks, and starting from the third week of the diet, mice received intraperitoneal injections of PD-1 antibody or rat IgG, 200 g/mouse, twice a week for 3 weeks before all the tissue collections. Serum lipids did not differ significantly between the 2 groups at time of euthanization ( Supplemental Table II ).
PD-1 antibody treatment did not change the lesion size development, but it significantly increased lesional CD4 ϩ and CD8 ϩ T cells compared with mice receiving control IgG at 5 weeks of diet (Figure 5a and 5b ). The two groups had similar lesional macrophage and SMC contents (Figure 5a and 5b, bottom panel).
Evaluation of iliac lymph nodes showed that mice receiving anti-PD-1 antibody treatment developed larger nodes with more CD4 ϩ T cells and CD8 ϩ T cells (Figure 6a, 6b, and 6e ), FACS analyses of activation markers on T cells revealed more CD44 ϩ and IFN-␥ producing CD4 ϩ and CD8 ϩ T cells (Figure 6c, 6d, 6f, and 6g ) in the anti-PD-1-treated group. Moreover, the percentage of splenic IFN-␥ producing CD4 ϩ T cells and CD8 ϩ T cells was significantly higher in the mice treated with anti-PD-1 antibody compared with the control IgG treated mice (data not shown), although the total percentages of splenic CD4 ϩ T cells and CD8 ϩ T cells were similar in both groups of mice. 
PD-L1/2 Deficiency in Bone Marrow-Derived Cells Results in Enhanced Atherosclerotic Lesion Inflammation
We have previously reported that cholesterol diet-fed Pd-l1/ 2 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice had more lesion development and more lesion inflammation than Ldlr Ϫ/Ϫ controls. 11 To assess whether PD-L1 and PD-L2 expression on bone marrowderived cells was responsible for regulation of proatherogenic T-cell responses, we prepared Pd-l1/2 Ϫ/Ϫ Ldlr ϩ/ϩ 3Ldlr Ϫ/Ϫ and control Pd-l1/2 ϩ/ϩ Ldlr ϩ/ϩ 3Ldlr Ϫ/Ϫ bone marrow chimeras. Hematopoietic reconstitution with donor cells was confirmed by polymerase chain reaction detection of the wild-type Ldlr allele in an aliquot of blood collected 4 weeks after bone marrow transplantation (Supplemental Figure IIa) . The rest of the blood was lysed and cultured with or without IFN-␥ stimulation overnight to induce PD-L1 expression. FACS analysis showed that PD-L1 was expressed at similar levels in all the wild-type to Ldlr Ϫ/Ϫ chimeras after IFN-␥ treatment, whereas no PD-L1 was detected in all Pd-l1/ 2 Ϫ/Ϫ 3Ldlr Ϫ/Ϫ chimeras (Pd-L1/2 Ϫ/Ϫ chimeras) (Supplemental Figure IIb ). All these data indicated a successful reconstitution. Therefore, we started feeding the chimeras with the cholesterol diet at this point.
After 10 weeks of cholesterol diet feeding, the bone marrow chimeras were euthanized, and aortic root lesions were analyzed. Serum lipids did not differ significantly between the 2 groups at that time ( Supplemental Table III ). Lesion size did not differ between recipients of Pd-l1/2 ϩ/ϩ or Pd-l1/2 Ϫ/Ϫ marrow (Supplemental Figure IIIa Strikingly, CD8 ϩ T cells were abundant in the lesions of Pd-l1/2 Ϫ/Ϫ marrow recipients, whereas CD8 ϩ T cells were scarce in the wild-type to Ldlr Ϫ/Ϫ chimeras. This result is consistent with our previous findings in the hypercholesterolemic Pd-l1/2 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice. 11 There was no difference in the expression of activation markers on splenic or iliac node T cells between the 2 groups, and the T cells from spleen and nodes of both groups proliferated the same amount and secreted comparable amounts of cytokines in response to in vitro reactivation by ␣CD3 or oxLDL. Furthermore, there was no evidence of increased systemic inflammation in either group, because plasma cytokines were mostly undetectable (data not shown).
Marked Increases in Both CD4 ؉ and CD8 ؉ T Cells Are Consistently Seen in Atherosclerotic Lesions of Ldlr ؊/؊ Mice With Impaired PD-L/PD-1 Signaling
To further characterize the lesional infiltrating CD4 ϩ cells and CD8 ϩ cells, we performed double immunofluorescence staining for CD3 and CD4 or CD8 in aortic sinus lesions from Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice, anti-PD-1-treated mice, and Pd-l1/2 Ϫ/Ϫ bone marrow chimeras, as well as appropriate controls. Confocal analyses of these stained lesions showed marked increases in both CD4 ϩ and CD8 ϩ T cells in mice with deficient or blocked PD-1 pathway (Supplemental Figure IV) . 
PD-1 Is Upregulated on Aortic T Cells in Hypercholesterolemic Ldlr ؊/؊ Mice
We examined whether diet-induced hypercholesterolemia could induce increased PD-1 expression in T cells from aortic lesions. Pooled aortas from Ldlr Ϫ/Ϫ mice fed either a cholesterol diet or a control diet for 8 weeks were enzymatically digested, and the recovered leukocytes were stained for CD3, CD8, and PD-1. The enzymatic digestion rendered CD4 undetectable, and we therefore judged that a large majority of the CD3 ϩ CD8 Ϫ cells were CD4 ϩ T cells. FACS analyses indicated that the cholesterol diet induced an increase in aortic wall T cells, including CD3 ϩ CD8 ϩ T cells and CD3 ϩ CD8 Ϫ T cells (Supplemental Figure Va to Vc). More T cells from hypercholesterolemic aortas expressed PD-1 than T cells from aortas of Ldlr Ϫ/Ϫ mice fed the control diet (Supplemental Figure Vd and Ve).
Discussion
In this study, we established a clear role for the PD-1 in modulating experimental atherosclerosis in Ldlr Ϫ/Ϫ mice. The influence of the PD-1 pathway on atherosclerosis was examined directly using 2 different approaches, complete genetic loss of PD-1 receptor and treatment with blocking antibody to PD-1. In addition, we used bone marrow chimeras to study the effects of a lack of PD-1 receptors PD-L1/ PD-L2 only on hematopoietically derived cells. Our data from all 3 approaches indicate that the PD-1 pathway tightly controls lesional T-cell responses and restrains a potentially robust CD8 ϩ T-cell response, which is usually minimal in mice when this coinhibitory pathway is intact.
PD-1 is a well-characterized receptor on T cells for PD-L1 and PD-L2. PD-L1 also has another receptor, B7-1, 4 and a second receptor for PD-L2 has been proposed but not yet published. 13 PD-1 is an activation antigen that is upregulated by T-cell activation and returns to basal levels following antigen clearance. In chronic infection and cancer, PD-1 remains high. Thus, the PD-1 molecule has been recognized as a hallmark of T-cell exhaustion, and PD-1-expressing antigen-specific T cells are dysfunctional in cytokine production and proliferation on antigen restimulation in a variety of viral infections. 7, 14, 21 The role of PD-1 in atherosclerosis has not been studied previously.
Our data comparing hypercholesterolemic Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice establish that PD-1 exerts significant antiinflammatory and atheroprotective effects and is the likely relevant receptor for the antiinflammatory and atheroprotective effects of PD-L1 or PD-L2 that we have previously observed. 11 The influence of PD-1 is manifest early in disease progression, because we observed marked increases in both CD4 ϩ T cells and CD8 ϩ T cells and macrophages in the aortic lesions in the PD-1-deficient mice after only 5 weeks of diet. Analyses of iliac node T-cell numbers, phenotype, proliferation, and cytokine secretion at 5 weeks indicate early dysregulation of systemic immune responses to the hypercholesterolemia in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice. These data indicate that PD-1 deficiency results in an exaggerated T cellmediated immune response in the early stages of hypercholesterolemia and atherosclerosis. After 10 weeks of diet, the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ lesion phenotype was more striking, with larger lesional size, outward aortic root remodeling, and increased inflammatory cell infiltration, including a remarkable number of CD8 ϩ T cells, as well as more apoptosis in the lesion. At the 10-week time point, splenic CD4 ϩ and CD8 ϩ T cells from Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice expressed higher levels than the Ldlr Ϫ/Ϫ control mice of mRNAs indicative of functional activation, including Ifng, Tnf, Ccr5, Ccr6, and Cxcr3. Furthermore, the detection of elevated levels of serum TNF-␣ in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ after 10 weeks of cholesterol diet is also consistent with continued profound dysregulation of the T cell-mediated immune response. Based on the cytokine profiles from either sera or supernatant of cultured cells, there was no obvious change in the balance of Th1 and Th2 cells when PD-1 deficient. We also did not detect any difference in numbers of CD4 ϩ FOXP3 ϩ cells between Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice either at 5 or 10 weeks, despite evidence suggesting PD-1 influences regulatory T-cell development and functions. 22 Overall, it appears that PD-1 plays a direct role in inhibiting activation of proatherogenic T cells.
The robust increase in lesion CD8 ϩ T cells seen in lesions of the PD-1-deficient mice suggests that there may have been more CTL-mediated cytotoxicity in those lesions. Although at 10 weeks, lesion size was greater in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ mice, there was not a concomitant increase in lesional SMC. We did observe more apoptotic lesional SMC in the Pd1 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ controls, which may explain why SMC content did not increase, and this finding is consistent with more CTL-mediated cytotoxicity. In vitro assay also confirmed that PD-1-deficient CD8 ϩ T cells are more potent killers of mouse aortic SMC.
Our finding that PD-1 expression is upregulated in aortic T cells in cholesterol diet-fed Ldlr Ϫ/Ϫ mice compared with control diet-fed mice suggests that chronic exposure to atheroantigens may lead to a partial suppression of CD4 ϩ and marked suppression of CD8 ϩ T-cell responses to these antigens. Specific peptides that may drive proatherogenic T-cell response are not well characterized, and therefore we could not examine PD-1 expression or T-cell exhaustion on tetramer-identified T cells, as has been done for viral-specific T cells in mice and humans. 7, 23 Given the phenotype of the PD-1-deficient Ldlr Ϫ/Ϫ mice, we reasoned that antibody-mediated blockade of PD-1 may aggravate atherosclerotic lesion inflammation. Our results from short-term injection of rat anti-mouse PD-1 antibody into hypercholesterolemic Ldlr Ϫ/Ϫ mice confirmed our prediction. The antibody-treated mice showed increases in lesional CD4 ϩ and CD8 ϩ T cells similar to those that we saw in the PD-1-deficient Ldlr Ϫ/Ϫ mice. There was also a remarkable effect of this short-term PD-1 blockade on iliac lymph node T-cell activation. We do not consider the lack of increase lesion size in the mice treated with anti-PD-1 Ig a significant finding, given the limited time for which we could treat the mice because of development of mouse anti-rat Ig responses. Furthermore, plaque inflammation may be more clinically relevant than plaque growth in the clinical context of treatment of patients.
We found that Ldlr Ϫ/Ϫ chimeras with Pd-l1/2 Ϫ/Ϫ bone marrow developed aortic lesions with more T cells and macrophages than did control chimeras with Pd-l1/2 ϩ/ϩ bone marrow but similar plaque sizes in the 2 groups. This is in contrast to our previous study 11 in nonirradiated Pd-l1/2 Ϫ/Ϫ / Ldlr Ϫ/Ϫ mice, which showed both enhanced lesion inflammation and lesion size. The enhanced lesion inflammation but comparable lesion size in the current study may reflect the influence of irradiation on lesion development, which we and others have found to be generally reduced compared with nonirradiated mice at relatively early time points. 24 Because PD-L1 is also expressed on non-bone marrow-derived cells, including EC, it is possible that PD-L1 deficiency on both nonhematopoietic and hematopoietic cells is required to influence lesion size. Remarkably, there were abundant CD8 ϩ T cells, almost as many as the CD4 ϩ T cells in the lesions of the Pd-l1/2 Ϫ/Ϫ bone marrow chimeras. We believe this is the finding of greatest translational significance in this experiment, given that plaque inflammation is tightly associated with acute coronary syndromes. In this study, the lack of hematopoietic PD-L likely impaired regulatory functions of lesional antigen presenting cells interacting with PD-1 ϩ T cells.
In summary, our data demonstrate that PD-1 plays a significant role in regulating both CD4 ϩ and CD8 ϩ T-cell responses in experimental atherosclerosis. Furthermore, CD8 ϩ T cells, which are usually difficult to detect in mouse lesions and less common than CD4 ϩ T cells, become prominent when PD-1 is absent or blocked. The data suggest that PD-1 agonists could have therapeutic benefit for exacerbations of atherosclerotic lesion inflammation, such as in acute coronary syndromes. Conversely, humanized functionblocking anti-PD-1 antibody therapies are being developed to enhance T-cell responses in patients with cancers or chronic viral infections, such as HIV and hepatitis C. Patients with HIV are at elevated risk for coronary artery disease and myocardial infarction compared with noninfected individuals, and highly active antiretroviral therapy leads to dyslipidemia Figure 6 . Effects of PD-1 blocking antibody treatment on immune responses of the hypercholesterolemic Ldlr Ϫ/Ϫ mice. a, Comparison of iliac lymph node cell counts from Ldlr Ϫ/Ϫ mice treated with PD-1 antibody or rat IgG. b to g, FACS analyses for numbers of total CD4 ϩ (b), CD8 ϩ (e) T cells and a fraction of CD44 (c and f), and IFN-␥ producing CD4 ϩ and CD8 ϩ T cells (d and g) in the iliac lymph nodes of Ldlr Ϫ/Ϫ mice receiving either PD-1 antibody or rat IgG treatment after 5 weeks of cholesterol diet. Horizontal bars represent the mean value for each group. Differences between 2 groups of mice were analyzed by the Mann-Whitney test. and insulin resistance. 25 It will therefore be important to consider the potential added risk of deregulating plaquebased T-cell responses by PD-1 blockade.
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